Although AG-825 is not applicable in vivo, as the compound lacks sufficient stability in live tissues41, the impact of its combination with GroA on cancer cells constitutes a proof of concept, and it can be later replaced by other ErbB2-inhibiting agents and clinical drugs, such as Herceptin42,43. The gene discussed is CXCL1; the disease is cancer.